News

As FDA considers new guidelines on pharmaceutical product marketing, a new study found that pharma makers may not be following current FDA ad regulations.

The new global DNA registry could help enable more precise treatments and identify who’s at risk for certain health problems.

Over the past few months, several new diabetes treatments have been approved by FDA. Here are the top 3 novel drugs for diabetes.

A new study shows efforts to reduce prescription opioid use in adults has not curtailed the incidence of pediatric opioid ingestions. Find out why.

Reduce readmissions by focusing on better engagement with patients and improving coordination from inpatient to outpatient settings.

Patients are the catalysts to interoperability changes, according to the Council of Accountable Physician Practices, an affiliate organization of the American Medical Group Foundation.

Before investing in new interoperability solutions, executives need to consider these four things.

When caring for cancer patients, improving care coordination in these two areas is key-and it can help reduce healthcare costs.

Unfortunately, the issue for many vets who experience trauma is that the mental health services they need are too far away from home. Here’s one solution.

About half of states have transitioned at least some Medicaid beneficiaries away from fee-for-service (FFS) drug programs into drug plans integrated with managed care. Our policy analyst shares why he believes more should do so.

A new FDA-approved drug offers new hope for patients with multidrug-resistant HIV-1 infection.

A new report highlights physical, social, and economic challenges of migraine.

UnitedHealthcare will pass on pharmacy discounts directly to some consumers, signaling the next wave of disruption in healthcare, say industry watchers.

FDA approved the first direct-to-consumer test for three specific BRCA1/BRCA2 breast cancer gene mutations.

There is no cure for HIV, but with proper medical treatment, the disease can be controlled.

Rideshare giants Uber and Lyft partner with providers to help get patients to their medical appointments, as well as improve the overall patient experience. Here’s five takeaways from industry watchers.

The Cigna-Express Scripts deal may signal a move to more vertical and horizontal healthcare deals. Here’s what else it means.

HHS Secretary Alex M. Azar II lays out top four HHS initiatives and calls on payers and providers to align.

Sadly, President Trump has issued an executive order to expand these plans under the guise of consumer choice and lower costs.

This first article in our new leadership series explores how managed care executives can cultivate smart ideas and stay ahead of the competition.

A new study has eye-opening findings on the use of buprenorphine induction in an opioid-dependent population with commercial benefit coverage.

During the worst flu season in years, FDA is warning consumers about fraudulent and counterfeit flu and antiviral products from online pharmacies.

In a rare move, pharmaceutical manufacturers voluntarily recalled their drug to treat multiple sclerosis after reports of serious brain inflammation in patients.

The first radioactive drug to treat a certain type of cancer is among the top 3 new drug approvals for cancer. Here are the other top cancer drug approvals so far in 2018.

Biologics, early treatment, and lifestyle choices take the spotlight in rheumatoid arthritis advances.

Reducing hospital readmissions requires just the right mix of clinical expertise and predictive analytics. Here are two health systems that are hitting their stride.

Your net promoter score could be influencing your business. Here’s what it is and how to improve it.

A lack of national standards and less than optimal oversight of many inpatient, opioid addiction rehabilitation programs is raising questions about the level of services, personnel, and quality of care many patients are receiving.

Genetic testing is playing a growing role in diagnosing and treating diseases, particularly when it comes to certain cancers and rheumatic conditions.

Switzerland-based pharma company Roche’s $1.9 billion purchase of tech company Flatiron Health signifies Big Pharma’s need for data.